Skip to main content

Advertisement

SpringerLink
Log in

Guinea pig complement potently measures vibriocidal activity of human antibodies in response to cholera vaccines

  • Microbial Pathogenesis and Host-Microbe Interaction
  • Published:
Journal of Microbiology Aims and scope Submit manuscript

Abstract

The vibriocidal assay using guinea pig complement is widely used for the evaluation of immune responses to cholera vaccines in human clinical trials. However, it is unclear why guinea pig complement has been used over human complement in the measurement of vibriocidal activity of human sera and there have not been comparison studies for the use of guinea pig complement over those from other species. Therefore, we comparatively investigated the effects of complements derived from human, guinea pig, rabbit, and sheep on vibriocidal activity. Complements from guinea pig, rabbit, and human showed concentration-dependent vibriocidal activity in the presence of quality control serum antibodies. Of these complements, guinea pig complement was the most sensitive and effective over a wide concentration range. When the vibriocidal activity of complements was measured in the absence of serum antibodies, human, sheep, and guinea pig complements showed vibriocidal activity up to 40-fold, 20-fold, and 1-fold dilution, respectively. For human pre- and post-vaccination sera, the most potent vibriocidal activity was observed when guinea pig complement was used. In addition, the highest fold-increases between pre- and post- vaccinated sera were obtained with guinea pig complement. Furthermore, human complement contained a higher amount of V. cholerae- and its lipopolysaccharide-specific antibodies than guinea pig complement. Collectively, these results suggest that guinea pig complements are suitable for vibriocidal assays due to their high sensitivity and effectiveness to human sera.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  • Ahmed, S., Bardhan, P.K., Iqbal, A., Mazumder, R.N., Khan, A.I., Islam, M.S., Siddique, A.K., and Cravioto, A. 2011. The 2008 cholera epidemic in Zimbabwe: experience of the icddr,b team in the field. J. Health Popul. Nutr. 29, 541–546.

    Article  PubMed  PubMed Central  Google Scholar 

  • Anh, D.D., Canh, D.G., Lopez, A.L., Thiem, V.D., Long, P.T., Son, N.H., Deen, J., von Seidlein, L., Carbis, R., Han, S.H., et al. 2007. Safety and immunogenicity of a reformulated Vietnamese bivalent killed, whole-cell, oral cholera vaccine in adults. Vaccine 25, 1149–1155.

    Article  CAS  PubMed  Google Scholar 

  • Attridge, S.R., Johansson, C., Trach, D.D., Qadri, F., and Svennerholm, A.M. 2002. Sensitive microplate assay for detection of bactericidal antibodies to Vibrio cholerae O139. Clin. Diagn. Lab. Immunol. 9, 383–387.

    CAS  PubMed  PubMed Central  Google Scholar 

  • Aung, K.M., Sjostrom, A.E., von Pawel-Rammingen, U., Riesbeck, K., Uhlin, B.E., and Wai, S.N. 2016. Naturally occurring IgG antibodies provide innate protection against Vibrio cholerae bacteremia by recognition of the outer membrane protein U. J. Innate Immun. 8, 269–283.

    Article  CAS  PubMed  Google Scholar 

  • Baumgarten, A. 1980. Viral immunodiagnosis. Yale J. Biol. Med. 53, 71–83.

    CAS  PubMed  PubMed Central  Google Scholar 

  • Blanco, L.P. and Dirita, V.J. 2006. Antibodies enhance interaction of Vibrio cholerae with intestinal M-like cells. Infect. Immun. 74, 6957–6964.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Boutonnier, A., Dassy, B., Dumenil, R., Guenole, A., Ratsitorahina, M., Migliani, R., and Fournier, J.M. 2003. A simple and convenient microtiter plate assay for the detection of bactericidal antibodies to Vibrio cholerae O1 and Vibrio cholerae O139. J. Microbiol. Methods 55, 745–753.

    Article  CAS  PubMed  Google Scholar 

  • Butler, S.M. and Camilli, A. 2005. Going against the grain: chemotaxis and infection in Vibrio cholerae. Nat. Rev. Microbiol. 3, 611–620.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Chen, W.H., Greenberg, R.N., Pasetti, M.F., Livio, S., Lock, M., Gurwith, M., and Levine, M.M. 2014. Safety and immunogenicity of single-dose live oral cholera vaccine strain CVD 103-HgR, prepared from new master and working cell banks. Clin. Vaccine Immunol. 21, 66–73.

    Article  PubMed  PubMed Central  Google Scholar 

  • Chin, C.S., Sorenson, J., Harris, J.B., Robins, W.P., Charles, R.C., Jean-Charles, R.R., Bullard, J., Webster, D.R., Kasarskis, A., Peluso, P., et al. 2011. The origin of the Haitian cholera outbreak strain. N. Engl. J. Med. 364, 33–42.

    Article  CAS  PubMed  Google Scholar 

  • Cohen, I.R. and Norins, L.C. 1968. Antibiodies of the IgG, IgM, and IgA classes in newborn and adult sera reactive with Gram-negative bacteria. J. Clin. Invest. 47, 1053–1062.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Finkelstein, R.A. 1962. Vibriocidal Antibody Inhibition (VAI) analysis: A technique for the identification of the predominant vibriocidal antibodies in serum and for the detection and identification of Vibrio cholerae antigens. J. Immunol. 89, 264–271.

    CAS  Google Scholar 

  • Kanungo, S., Lopez, A.L., Ali, M., Manna, B., Kim, D.R., Mahapatra, T., Holmgren, J., Dhingra, M.S., Weirzba, T.F., Nair, G.B., et al. 2014. Vibriocidal antibody responses to a bivalent killed whole-cell oral cholera vaccine in a phase III trial in Kolkata, India. PLoS One 9, e96499.

    Article  Google Scholar 

  • Kanungo, S., Paisley, A., Lopez, A.L., Bhattacharya, M., Manna, B., Kim, D.R., Han, S.H., Attridge, S., Carbis, R., Rao, R., et al. 2009}. Immune responses following one and two doses of the reformulated, bivalent, killed, whole-cell, oral cholera vaccine among adults and children in Kolkata, India: a randomized, placebocontrolled trial. Vaccine 27, 6887–6893.

    Article  CAS  PubMed  Google Scholar 

  • Mahalanabis, D., Lopez, A.L., Sur, D., Deen, J., Manna, B., Kanungo, S., von Seidlein, L., Carbis, R., Han, S.H., Shin, S.H., et al. 2008. A randomized, placebo-controlled trial of the bivalent killed, whole-cell, oral cholera vaccine in adults and children in a cholera endemic area in Kolkata, India. PLoS One 3, e2323.

    Article  Google Scholar 

  • Muschel, L.H. and Treffers, H.P. 1956. Quantitative studies on the bactericidal actions of serum and complement. II. Some implications for the mechanism of the bactericidal reaction. J. Immunol. 76, 11–19.

    CAS  PubMed  Google Scholar 

  • Nguyen, V.D., Sreenivasan, N., Lam, E., Ayers, T., Kargbo, D., Dafae, F., Jambai, A., Alemu, W., Kamara, A., Islam, M.S., et al. 2014. Cholera epidemic associated with consumption of unsafe drinking water and street-vended water-Eastern Freetown, Sierra Leone, 2012. Am. J. Trop. Med. Hyg. 90, 518–523.

    Article  PubMed  PubMed Central  Google Scholar 

  • Ramamurthy, T., Yamasaki, S., Takeda, Y., and Nair, G.B. 2003. Vibrio cholerae O139 Bengal: odyssey of a fortuitous variant. Microbes Infect. 5, 329–344.

    Article  PubMed  Google Scholar 

  • Saddler, J.N. and Wardlaw, A.C. 1978. Superiority of human complement for assaying bacterial lipopolysaccharides by their anticomplementary activity. Experientia 34, 1227–1228.

    Article  CAS  PubMed  Google Scholar 

  • Sethi, J., Pei, D., and Hirshaut, Y. 1981. Choice and specificity of complement in complement fixation assay. J. Clin. Microbiol. 13, 888–890.

    CAS  PubMed  PubMed Central  Google Scholar 

  • Shin, S., Desai, S.N., Sah, B.K., and Clemens, J.D. 2011. Oral vaccines against cholera. Clin. Infect. Dis. 52, 1343–1349.

    Article  PubMed  Google Scholar 

  • Stroeher, U.H., Karageorgos, L.E., Morona, R., and Manning, P.A. 1992. Serotype conversion in Vibrio cholerae O1. Proc. Natl. Acad. Sci. USA 89, 2566–2570.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Svennerholm, A.M., Jertborn, M., Gothefors, L., Karim, A.M., Sack, D.A., and Holmgren, J. 1984. Mucosal antitoxic and antibacterial immunity after cholera disease and after immunization with a combined B subunit-whole cell vaccine. J. Infect. Dis. 149, 884–893.

    Article  CAS  PubMed  Google Scholar 

  • Vu, D.T., Hossain, M.M., Nguyen, D.S., Nguyen, T.H., Rao, M.R., Do, G.C., Naficy, A., Nguyen, T.K., Acosta, C.J., Deen, J.L., et al. 2003. Coverage and costs of mass immunization of an oral cholera vaccine in Vietnam. J. Health Popul. Nutr. 21, 304–308.

    PubMed  Google Scholar 

  • Weidanz, W.P. and Landy, M. 1963. A simplified method for bactericidal assay of natural antibodies against Gram-negative bacteria. Proc. Soc. Exp. Biol. Med. 113, 861–867.

    Article  CAS  PubMed  Google Scholar 

  • Yang, J.S., Choi, S., Kim, D.D., Kang, S.S., Yun, C.H., Lee, K., and Han, S.H. 2009. A duplex vibriocidal assay to simultaneously measure bactericidal antibody titers against Vibrio cholerae O1 Inaba and Ogawa serotypes. J. Microbiol. Methods 79, 289–294.

    Article  CAS  PubMed  Google Scholar 

  • Yang, J.S., Kim, H.J., Yun, C.H., Kang, S.S., Im, J., Kim, H.S., and Han, S.H. 2007. A semi-automated vibriocidal assay for improved measurement of cholera vaccine-induced immune responses. J. Microbiol. Methods 71, 141–146.

    Article  CAS  PubMed  Google Scholar 

  • Zollinger, W.D. and Mandrell, R.E. 1983. Importance of complement source in bactericidal activity of human antibody and murine monoclonal antibody to meningococcal group B polysaccharide. Infect. Immun. 40, 257–264.

    CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Oral Microbiology and Immunology, DRI, and BK21 Plus Program, School of Dentistry, Seoul National University, Seoul, 08826, Republic of Korea

    Kyoung Whun Kim, Soyoung Jeong, Ki Bum Ahn & Seung Hyun Han

  2. Department of Agricultural Biotechnology and Research Institute for Agriculture and Life Sciences, Seoul National University, Seoul, 08826, Republic of Korea

    Kyoung Whun Kim & Cheol-Heui Yun

  3. Clinical Research Laboratory, Sciences Unit, International Vaccine Institute, Seoul, 08826, Republic of Korea

    Kyoung Whun Kim & Jae Seung Yang

  4. Research Division for Biotechnology, Korea Atomic Energy Research Institute, Jeongeup, 56212, Republic of Korea

    Ki Bum Ahn

  5. Institute of Green Bio Science Technology, Seoul National University, Seoul, 08826, Republic of Korea

    Cheol-Heui Yun

Authors
  1. Kyoung Whun Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Soyoung Jeong
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ki Bum Ahn
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Jae Seung Yang
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Cheol-Heui Yun
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Seung Hyun Han
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Seung Hyun Han.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kim, K.W., Jeong, S., Ahn, K.B. et al. Guinea pig complement potently measures vibriocidal activity of human antibodies in response to cholera vaccines. J Microbiol. 55, 973–978 (2017). https://doi.org/10.1007/s12275-017-7478-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12275-017-7478-0

Keywords

Search

Navigation